Neutralizing antibodies (NAbs) are critical human immune defense mechanisms against viral infections. NAbs can bind to sites on the virus and inhibit entry of that virus into the host. It is a key parameter to evaluate COVID-19 vaccine efficacy per Guidelines from Development and Licensure of Vaccines to Prevent COVID-19 by FDA.
In this webinar, Dr. Yanfeng Li will discuss about limitations of traditional serology methods; post vaccination NAb evaluation; NAb longevity in COVID-19 infected & vaccinated individuals; surface of new SARS-CoV-2 variants; and challenges we face in COVID-19 management.
We will also review the unique features of surrogate virus neutralization test (sVNT) technology, and potential to leverage cPass™ as COVID-19 'exit strategy' to reopen the economy and society.
Dr. Yanfeng Li is the head of business development (IVD) in GenScript Asia Pacific. She is well trained in Cellular biology & Immunology, with extensive research experience in signalling pathways determining B cell biology and T cell functionality. She authored in more than 10 world renowned journals and led >50 successful clinical trials connecting insights from consumer behaviour, skin biology and intervention efficacy.